The ema begins the review of the pfizer-biontech covid vaccine adapted to variants

LONDON, Aug 9 (Reuters) – The European Medicines Agency (EMA) has launched a rolling review of a vaccine from Pfizer and BioNTech tailored to variants of COVID-19, it said on Tuesday.

The so-called bivalent vaccine targets two strains of the SARS-CoV-2 virus that are behind COVID-19, the original strain first identified in China and the BA.4 and BA.5 variants of omicron, which are currently behind most cases in the region.

A rolling review means that the EMA evaluates data as it becomes available and the process continues until there is enough data for a formal marketing application. (Reporting by Natalie Grover in London; editing by Louise Heavens; translated by José Muñoz in the Gdańsk newsroom)

–